Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02985957
Title A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

prostate cancer

Therapies

Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | AUT


No variant requirements are available.